Prognostic Value of S-100B in Malignant Melanoma
Author Information
Author(s): JMG Bonfrer, CM Korse, OE Nieweg, EM Rankin
Primary Institution: The Netherlands Cancer Institute
Hypothesis
The study investigates the prognostic value of serum S-100B levels in patients with malignant melanoma.
Conclusion
The measurement of S-100B as a tumor marker is clinically significant for managing patients with cutaneous malignant melanoma.
Supporting Evidence
- 79% of patients with metastasized disease had elevated S-100B levels.
- Patients with limited disease had a significantly lower risk of early death compared to those with elevated S-100B levels.
- S-100B was shown to be a better parameter than neuron-specific enolase for distinguishing between disease stages.
- Median survival for patients with elevated S-100B levels was 7 months compared to over 12 years for those with normal levels.
Takeaway
Doctors can use a blood test to check a protein called S-100B to see how serious melanoma is and how long patients might live.
Methodology
Serum S-100B concentrations were measured in 251 patients with malignant melanoma using a sensitive luminometric immunoassay.
Limitations
The study's findings may be limited by the relatively small number of control subjects and the specific patient population.
Participant Demographics
The study included 251 patients, 143 females and 108 males, aged 12 to 87 years, with a mean age of 50.6 years.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.0001
Want to read the original?
Access the complete publication on the publisher's website